Home Featured Page 156

Featured

Latest

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Combating Suicidality: A Role for Psilocybin and Ayahuasca?

PT361 – Jason Slot, Ph.D. – Mycology and Evolutionary Genomics

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released...

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common...

Psychedelic Bulletin #119: More Misery for MindMed; Another Psychedelics Co. Ceases...

Reunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder...

Whole-Body Effects of Psychedelics Part 3 – The Heart

Psyence Group Completes Export of Psilocybin Mushrooms to Portugal

Numinus to Participate in the Cantor Neurology & Psychiatry Conference on...

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psychedelics & Society

Combating Suicidality: A Role for Psilocybin and Ayahuasca?

PT361 – Jason Slot, Ph.D. – Mycology and Evolutionary Genomics

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released...

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common...

Psychedelic Bulletin #119: More Misery for MindMed; Another Psychedelics Co. Ceases...

Reunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder...

Whole-Body Effects of Psychedelics Part 3 – The Heart

Psyence Group Completes Export of Psilocybin Mushrooms to Portugal

Numinus to Participate in the Cantor Neurology & Psychiatry Conference on...

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY